Is Cosmecca Korea profitable in 2026?

Yes. In Q1 2026 Cosmecca Korea posted revenue of ₩185.1 billion, up 56.4% year over year, with operating profit rising 78% to ₩21.9 billion, reported May 13, 2026.

Who owns Cosmecca Korea?

Cosmecca Korea has traded publicly on KOSDAQ under ticker 241710 since October 2016. Its largest institutional shareholder is the National Pension Service of Korea, holding roughly 10% as of August 5, 2025.

Could AI replace Cosmecca Korea?

No. Cosmecca manufactures physical, GMP-regulated cosmetics under regulatory liability that AI cannot assume. It uses AI internally, cutting a 4-hour ingredient check to 10 seconds and reducing defect rates about 30% at its Eumseong plant, reported January 22, 2026.

Who is Cosmecca Korea's biggest competitor?

Kolmar Korea ranks first among Korean cosmetics ODMs, with Cosmecca third as of November 2025. Cosmax, ranked second, has pulled ahead on customer-facing AI, winning a CES 2026 award for a skin-diagnosis device.

Did Cosmecca Korea's KOSPI listing move succeed?

No. The Korea Exchange rejected Cosmecca's preliminary bid to move its listing from KOSDAQ to KOSPI in September 2025; the company said it would instead focus on internal management improvements.

How exposed is Cosmecca Korea to China?

Significantly. In Q1 2026 Cosmecca's China business fell 27.1% due to raw-material and supplier delays, even as Korean-unit revenue rose 91.3% in the same quarter, reported May 13, 2026.

Consumer brands · South Korea

Cosmecca Korea Co., Ltd.

Korean cosmetics ODM/OEM, ranked #3, makes products for K-beauty brands like Anua, Medicube.

Hard to displace

Assessed 25 July 2026 · Evidence as of 25 July 2026

Strong structural protection; the business model survives ai pressure.

On the recordSince 25 July 2026 · Checkable from August 2026 · Every call on the record Checkpoint: Q2 2026 earnings release, watch China revenue recovery and margin trend

The call

Cosmecca rides the K-beauty wave with real factories and regulatory ties, but its lag on customer-facing AI tools versus Cosmax remains the open question.

Cosmecca Korea makes beauty products for other brands to sell under their own names. It is hard to replace because it owns factories, has government approvals, and builds long-term relationships with customers, but AI cannot do the hands-on manufacturing or take legal responsibility. The real danger is that Cosmax, its main competitor, is moving faster on AI tools that help brands design custom products and diagnose skin types. If Cosmecca does not launch its own AI tools in the next year or so, brands may start using Cosmax as their go-to partner instead.

Why

AI pressure: Cosmax customer-facing AI formulation and skin-diagnosis platform. Cosmax is moving faster on AI personalization tools that indie brands could adopt as default R&D infrastructure, leaving Cosmecca behind on that front. Could AI do the core job? Unlikely.

Bigger players: Kolmar Korea (#1 ODM by scale). Kolmar Korea already outscales Cosmecca in manufacturing capacity and client roster, competing for the same indie and global beauty brand contracts. Could a giant copy it? Probably.

What protects it. Capex-heavy manufacturing, GMP regulatory compliance, and a US foothold via Englewood Lab that AI cannot replicate or replace.

What would change this call

Cosmax launches or expands an AI-based skin-diagnosis or formulation platform for indie brand clients within 12-18 months. Would show Cosmax pulling ahead on tech-driven client acquisition versus Cosmecca.
Whether Anua, Medicube, or Beauty of Joseon shift order volume away from Cosmecca in upcoming quarterly filings. Would show client concentration risk materializing as real revenue loss.
China revenue trend in Cosmecca's Q2 2026 and later filings after the -27% Q1 2026 drop. Would show whether lost China volume is recovered or permanently ceded to competitors.

Key numbers

Q1 2026 revenue +56.4% YoY to ₩185.1B (2026-05-13)
China sales -27.1% vs Korea +91.3% in Q1 2026 (2026-05-13)
FY2025 revenue ₩640.9B, up 22.24% YoY (2026-07-03)

Named risks

China revenue fell 27.1% in Q1 2026 due to raw-material and supplier delays. Severity: high
Regulatory freeze on dual listings stalls any renewed KOSPI uplisting bid. Severity: medium
Revenue concentration on trend-driven indie brands like Anua, Medicube, Beauty of Joseon. Severity: medium
Cosmax outpacing Cosmecca on customer-facing AI personalization products. Severity: medium

Rivals, as read in July 2026

Rival	Direction	Evidence
Kolmar Korea	losing to	Ranked #1 Korean ODM by sales, ahead of Cosmecca's #3 position as of 2025-11-09
Cosmax	losing to	Cosmax won a CES 2026 award for AI skin-diagnosis device and expanded to Japan, per 2026-02-25 report
C&C International	contesting	Building new Cheongju plant targeting 2027 completion to challenge Cosmecca's #3 spot

Questions people ask

Is Cosmecca Korea profitable in 2026?: Yes. In Q1 2026 Cosmecca Korea posted revenue of ₩185.1 billion, up 56.4% year over year, with operating profit rising 78% to ₩21.9 billion, reported May 13, 2026.
Who owns Cosmecca Korea?: Cosmecca Korea has traded publicly on KOSDAQ under ticker 241710 since October 2016. Its largest institutional shareholder is the National Pension Service of Korea, holding roughly 10% as of August 5, 2025.
Could AI replace Cosmecca Korea?: No. Cosmecca manufactures physical, GMP-regulated cosmetics under regulatory liability that AI cannot assume. It uses AI internally, cutting a 4-hour ingredient check to 10 seconds and reducing defect rates about 30% at its Eumseong plant, reported January 22, 2026.
Who is Cosmecca Korea's biggest competitor?: Kolmar Korea ranks first among Korean cosmetics ODMs, with Cosmecca third as of November 2025. Cosmax, ranked second, has pulled ahead on customer-facing AI, winning a CES 2026 award for a skin-diagnosis device.
Did Cosmecca Korea's KOSPI listing move succeed?: No. The Korea Exchange rejected Cosmecca's preliminary bid to move its listing from KOSDAQ to KOSPI in September 2025; the company said it would instead focus on internal management improvements.
How exposed is Cosmecca Korea to China?: Significantly. In Q1 2026 Cosmecca's China business fell 27.1% due to raw-material and supplier delays, even as Korean-unit revenue rose 91.3% in the same quarter, reported May 13, 2026.

Timeline

2026-06-25Announced construction of AI autonomous manufacturing platform under SME-support program
2026-05-13Q1 2026 results: revenue ₩185.1B up 56.4% YoY, operating profit up 78% to ₩21.9B
2026-04-08Selected for ₩530M Robot Utilization Manufacturing Innovation Support Project
2026-03-27Raised Englewood Lab stake from 50% to 66.67% via tender offer
2026-03-17Developed world-first water-in-water emulsion sunscreen with Seoul National University of Science and Technology
2026-01-22Eumseong K-Smart Lighthouse Factory AI digital twin cuts 4-hour check to 10 seconds
2025-11-09Q3 2025 revenue ₩182.4B, +44% YoY, record quarterly high, ranked #3 Korean ODM
2025-09-02Korea Exchange rejected preliminary KOSPI uplisting bid
2025-05-19Selected for government AI-based personalized cosmetics platform consortium
2025-04-21Went live with Centric Software PLM system to cut development time ~30%

Revision history

25 July 2026

First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.

In the same band

Hermes International Compagnie Financiere Richemont Inditex (Zara)